Tenax Therapeutics, Inc. (TENX) Institutional Ownership

Ownership Summary

Tenax Therapeutics, Inc. (NASDAQ:TENX) has 46 institutional investors that have filed 13F reports for the period ending December 2025.

• Collectively, these holders controlled 17.7% of Tenax Therapeutics's outstanding shares in December 2025, up from 11.9% in September 2025.
• They increased total shares held in Tenax Therapeutics by 64.88% from the prior quarter, while the number of investors in TENX increased 109.09% year over year.
• Activity in TENX broke down as 30 buyers, 3 sellers, and 13 unchanged among 46 total holders.
• Altogether, these fund groups held 7.03Mn shares in TENX by December 2025, up by 2.76Mn shares quarter on quarter, and up 5.59Mn shares year over year.
• Janus Henderson Group Plc holds the largest position in TENX at 3.63Mn shares as of December 31, 2025, or 9.14% of shares outstanding.
• Leading buyers of Tenax Therapeutics shares for the quarter ending December 2025 were Janus Henderson Group Plc (3.46Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.95Mn), Venrock Adviser, LLC (1.68Mn), PERCEPTIVE ADVISORS LLC (1.01Mn), Stonepine Capital Management, LLC (963.32K).
• The largest sales of TENX for the quarter ending December 2025 came from DIADEMA PARTNERS LP (63.43K), SPHERA FUNDS MANAGEMENT LTD. (54.1K), Goldman Sachs Group Inc (12.96K), Corient Private Wealth LLC (12.39K), RTW INVESTMENTS, LP (8.1K).
• Per Business Quant data, the top 10 holders of Tenax Therapeutics for the quarter ending December 2025 are Janus Henderson Group Plc (3.63Mn), PRICE T ROWE ASSOCIATES INC /MD/ (2.95Mn), Venrock Adviser, LLC (1.68Mn), PERCEPTIVE ADVISORS LLC (1.45Mn), Ikarian Capital, LLC (1.02Mn), Stonepine Capital Management, LLC (975.2K), Logos Global Management LP (625.0K), Morgan Stanley (596.56K), Velan Capital Investment Management LP (583.33K), ADAGE CAPITAL PARTNERS GP, L.L.C. (540.13K).